Evivo™ Protects Babies From the Inside Out
Evivo is the Only Probiotic Clinically Proven to Restore Baby's Gut Microbiome
DAVIS, Calif., July 12, 2017 /PRNewswire/ -- Evolve BioSystems, Inc. announces the introduction of Evivo (www.evivo.com/press), the first and only probiotic clinically proven to restore a baby's gut microbiome to its original, natural state. Once daily Evivo helps develop a healthy immune system and metabolism to set up babies for healthier lives.
97% of Babies Missing Key Beneficial Gut Bacteria
The last 100 years have seen a dramatic change in the baby's gut microbiome. Past generations received a key beneficial bacteria - B. infantis - from mom at birth. Today, this transfer has been interrupted due to the unintentional consequences of antibiotics, C-section deliveries, and higher rates of formula feeding. As a result, 97% of babies no longer receive B. infantis, allowing for potentially harmful bacteria to dominate the gut microbiome. These potentially harmful bacteria are linked to higher risk for conditions like eczema, allergies, diabetes and obesity.
"As a parent and health care professional, I'll do anything to ensure my kids are growing strong and healthy," said Dr. Tanya Altmann, MD and Evivo spokesperson. "As we learn more about the infant gut microbiome and its influence over the development of the immune system, it's never been more important to restore the gut back to what nature intended."
The Power of Evivo (activated B. infantis EVC001)
Only Evivo (activated B. infantis) is clinically proven to increase beneficial bacteria, help reduce potentially harmful bacteria, and restore a baby's gut microbiome to its original, natural state.
The company's world-renowned scientists have dedicated more than a decade to understanding the infant gut microbiome and the relationship between B. infantis and breast milk. In addition to nourishing babies, breast milk also contains special carbohydrates that specifically promote the growth of B. infantis in the infant gut. Evivo (activated B. infantis) transforms these special carbohydrates into important nutrients for the baby and creates a protective environment in baby's gut.
"A healthy gut microbiome during the first months of life is critically important," said Tracy Shafizadeh, PhD, Director, Scientific Communications at Evivo. "It protects and supports baby's developing metabolism and immune system, setting up baby for lifelong health."
Parents and caregivers can mix Evivo powder with 3-5ml of breast milk and dropper-feed it to their baby each day. Evivo contains no artificial colors or dyes, flavors, preservatives or additives, and it is gluten free. Evivo is proudly made in the U.S.
"I recommend Evivo to my patients' babies as a part of their daily routine. I'm excited about its potential to have a major impact on the future of baby's health," concluded Dr. Altmann.
To learn more and purchase a starter kit, visit www.evivo.com/prshop. You can follow @EvivoHealth on Facebook, Instagram or Twitter.
About the Company Behind Evivo – Evolve BioSystems
Evolve BioSystems, Inc. is a privately-held microbiome company dedicated to developing the next generation of products to establish, restore, and maintain a healthy newborn gut microbiome. Evolve is a spin-out from the Foods for Health Institute (FFHI) at the University of California, Davis and builds on more than a decade of research into understanding the unique partnership of the infant gut microbiome and breast milk components. Having led to the discovery and development of products to resolve infant gut dysbiosis, Evolve's discovery platform is now being applied to solving gut dysbiosis throughout the human life cycle. Evolve completed a $9 million Series A capital raise in 2015, followed by an additional $20 million Series B capital raise in May 2017. Evolve has now completed a landmark proof-of-concept study demonstrating the efficacy of its initial proprietary offering, and is undertaking further clinical studies to build out a portfolio of microbiome-based solutions to support the lifelong health of newborns worldwide.
Media Contact:
Chey Bell
MSR Communications
Phone: 415-989-9000
E-mail: [email protected]
SOURCE Evolve BioSystems, Inc.
Share this article